IP Library Granted Patent US 7,709,654
Granted Patent B2
US 7,709,654 · App. 11/900,329 · Granted May 4, 2010

Process for producing oxazole, imidazole, pyrrazole boryl compounds

Assignee: Board of Trustees of Michigan State University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,709,654
App. No.
11/900,329
Granted
May 4, 2010
Kind
B2
Abstract

Process for the preparation of oxazole, imidazole, and pyraxole boryl compounds. The compounds are intermediates to functionalized compounds, both natural and synthetic which are cytotoxic, anticancer and antiviral agents.

Claims (53)

1. A process for producing an oxazole (I), imidazole (II), or pyrazole (III) boryl compound, the process comprising:

(a) reacting an oxazole (IV), imidazole (V), or pyrazole (VI) with an HB or B—B organic compound in a reaction mixture with a non-reactive solvent at a temperature between about 0° C. and 150° C. and in the presence of a catalytically effective amount of an iridium complex catalytic composition, the oxazole (IV), imidazole (V), or pyrazole (VI) having a structure according to formula IV, V, or VI, respectively:

wherein:

(i) R 1 is independently selected from the group consisting of hydrogen, boryl, halo, cyano, alkyl, alkoxy, thioalkyl, amino alkyl, acyl, alkyl aminoacyl, trifluoro alkyl, aryl, alkyl silyl, and containing 1 to 8 carbon atoms except for the halo group and boryl group,

(ii) R 2 is selected from the group consisting of methyl, isopropyl, triisopropylsilyl, phenyl, benzyl, para-methoxybenzyl, tert-butoxycarbonyl, (benzyloxy)carbonyl, N,N-dimethylaminosulfonyl, N,N-dimethylcarboxamide, para-toluenesulfonyl, and 9H-Fluoren-9-ylmethyloxycarbonyl; and

(iii) the iridium complex catalytic composition comprises an iridium complex of the formula: (BY) n -lr-(ligand) m , where n is equal to one to five, m is equal to one to three, excluding hydrogen, bonded to the iridium, BY is a boron moiety, the ligand is selected from the group consisting of a phosphorus organic ligand, an organic amine, an imine, a nitrogen heterocycle, and an ether, and the ligand is at least in part bonded to the iridium;

(b) forming the oxazole (I), imidazole (II), or pyrazole (III) boryl compound in the reaction mixture, the oxazole (I), imidazole (II), or pyrazole (III) boryl compound having a structure according to formula I, II, or III, respectively:

wherein:

(i) R 1 is independently selected from the group consisting of hydrogen, boryl, halo, cyano, alkyl, alkoxy, thioalkyl, amino alkyl, acyl, alkyl aminoacyl, trifluoro alkyl, aryl, alkyl silyl, and containing 1 to 8 carbon atoms except for the halo group and boryl group,

(ii) R 2 is selected from the group consisting of methyl, isopropyl, triisopropylsilyl, phenyl, benzyl, para-methoxybenzyl, tert-butoxycarbonyl, (benzyloxy)carbonyl, N,N-dimethylaminosulfonyl, N,N-dimethylcarboxamide, para-toluenesulfonyl, and 9H-Fluoren-9-ylmethyloxycarbonyl; and

(c) evaporating the solvent and portions of the reaction mixture which are volatile from the reaction mixture to produce the oxazole (I), imidazole (II), or pyrazole (III) boryl compound.

2. The process of claim 1 wherein the iridium complex catalytic composition is formed in the reaction mixture from an iridium complex of [Ir(OMe)(COD)] 2 , [Ir(Cl)(COD)] 2 , or (COD)(η 5 -indenyl)Ir, where COD is 1 ,5-cyclooctadine, complexed with a ligand selected from the group consisting of:

wherein R are each selected from the group consisting of hydrogen, linear alkyl containing 1 to 8 carbon atoms, branched alkyl containing 1 to 8 carbons, and a carbon in a cyclic structure, Y is a carbon, oxygen, nitrogen, or sulfur containing moiety, and G is a heteroatom containing group, multiple atom chain, or multiple atom ring.

3. The process of claim 1 wherein the iridium complex catalytic composition is formed in the reaction mixture from an iridium complex of [Ir(OMe)(COD)] 2 , [Ir(Cl)(COD)] 2 , or (COD)(η 5 -indenyl)Ir, where COD is 1,5-cyclooctadine, complexed with a ligand selected from the group consisting of:

wherein R are each selected from the group consisting of hydrogen, linear alkyl containing 1 to 8 carbon atoms, branched alkyl containing 1 to 8 carbons, and a carbon in a cyclic structure.

4. The process of claim 1 wherein the iridium complex catalytic composition is formed in the reaction mixture from an iridium complex of [Ir(OMe)(COD)] 2 , [Ir(Cl)(COD)] 2 , or (COD)(η 5 -indenyl)Ir, where COD is 1,5-cyclooctadine, complexed with a ligand selected from the group consisting of:

wherein R are each selected from the group consisting of hydrogen, linear alkyl containing 1 to 8 carbon atoms, branched alkyl containing 1 to 8 carbons, and a carbon in a cyclic structure, Y is a carbon, oxygen, nitrogen, or sulfur containing moiety, and Z is a carbon, oxygen, nitrogen, sulfur, or boron containing moiety or a multiple atom chain containing a carbon, oxygen, nitrogen, sulfur, or boron containing moiety.

5. The process of claim 1 wherein the iridium complex catalytic composition is formed in the reaction mixture from an iridium complex of [Ir(OMe)(COD)] 2 , [Ir(Cl)(COD)] 2 , or (COD)(η 5 -indenyl)Ir, where COD is 1,5-cyclooctadine, complexed with a ligand selected from the group consisting of:

wherein R are each selected from the group consisting of hydrogen, aryl, linear alkyl containing 1 to 8 carbon atoms, branched alkyl containing 1 to 8 carbons, alkoxy, or a carbon in a cyclic structure and Z is a carbon, oxygen, or nitrogen containing moiety or a multiple atom chain containing a carbon, oxygen, or nitrogen containing moiety.

6. The process of claim 1 wherein the iridium complex catalytic composition is formed in the reaction mixture from an iridium complex of [Ir(OMe)(COD)] 2 , [Ir(Cl)(COD)] 2 , or (COD)(η 5 -indenyl)Ir, where COD is 1,5-cyclooctadine, complexed with 4,4-di-t-butyl-2,2′-bipyridine (dtbpy).

7. The process of claim 1 wherein the iridium complex catalytic composition is formed in the reaction mixture from an iridium complex of [Ir(OMe)(COD)] 2 , [Ir(Cl)(COD)] 2 , or (COD)(η 5 -indenyl)Ir, where COD is 1,5-cyclooctadine, complexed with 1,2-bis(dimethylphospino)ethane.

8. The process of claim 1 wherein the non-reactive solvent is selected from the group consisting of aliphatic hydrocarbons, ethers, and combinations thereof.

9. The process of claim 1 wherein:

(i) the reaction mixture comprises the oxazole (IV) prior to reaction; and

(ii) the boryl compound formed in the reaction mixture comprises the oxazole (I) boryl compound.

10. The process of claim 1 wherein:

(i) the reaction mixture comprises the imidazole (V) prior to reaction; and

(ii) the boryl compound formed in the reaction mixture comprises the imidazole (II) boryl compound.

11. The process of claim 1 wherein:

(i) the reaction mixture comprises the pyrazole (VI) prior to reaction;

(ii) the boryl compound formed in the reaction mixture comprises the pyrazole (III) boryl compound;

(iii) R 1 at the 3-position and R 1 at the 4-position of the pyrazole (VI) and the pyrazole (III) boryl compound together are not hydrogen and hydrogen, respectively; and

(iv) R 1 at the 3-position and R 1 at the 4-position of the pyrazole (VI) and the pyrazole (III) boryl compound together are not alkyl and hydrogen, respectively.

12. An oxazole (I), imidazole (II), or pyrazole (III) boryl compound having a structure according to formula I, II, or III, respectively:

wherein:

(i) R 1 is independently selected from the group consisting of hydrogen, boryl, halo, cyano, alkyl, alkoxy, thioalkyl, amino alkyl, acyl, alkyl aminoacyl, trifluoro alkyl, aryl, alkyl silyl, and containing 1 to 8 carbon atoms except for the halo group and boryl group,

(ii) R 2 is selected from the group consisting of methyl, isopropyl, triisopropylsilyl, phenyl, benzyl, para-methoxybenzyl, tert-butoxycarbonyl, (benzyloxy)carbonyl, N,N-dimethylaminosulfonyl, N,N-dimethylcarboxamide, para-toluenesulfonyl, and 9H-Fluoren-9-ylmethyloxycarbonyl, and

(iii) BY is a boron moiety derived from an HB or B—B organic compound;

(iv) R 1 at the 2-position and R 1 at the 4-position of the oxazole (I) boryl compound together are not hydrogen and hydrogen, respectively;

(v) R 1 at the 2-position and R 1 at the 4-position of the imidazole (II) boryl compound together are not alkyl and hydrogen, respectively;

(vi) R 1 at the 3-position and R 1 at the 4-position of the pyrazole (III) boryl compound together are not hydrogen and hydrogen, respectively; and

(vii) R 1 at the 3-position and R 1 at the 4-position of the pyrazole (III) boryl compound together are not alkyl and hydrogen, respectively.

13. The compound of claim 12 wherein at least one R 1 substituent is a halo group.

14. The compound of claim 12 wherein at least one R 1 substituent is an aryl group.

15. The compound of claim 12 comprising the oxazole (I) boryl compound.

16. The compound of claim 12 , comprising an oxazole (I) boryl compound selected from the group consisting of:

and combinations thereof.

17. The compound of claim 12 , comprising the imidazole (II) boryl compound.

18. The compound of claim 12 , comprising an imidazole (II) boryl compound selected from the group consisting of:

and combinations thereof.

19. The compound of claim 12 , comprising the pyrazole (III) boryl compound.

20. The compound of claim 12 , comprising a pyrazole (III) boryl compound selected from the group consisting of:

and combinations thereof.

Assignments (2)
CONFIRMATORY LICENSE Recorded Sep 15, 2011
From: MICHIGAN STATE UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 026910/0537 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 13, 2007
From: SMITH, III MILTON R.; MALECZKA, JR., ROBERT E.; KALLEPALLI, VENKATA A.; ONYEOZILI, EDITH
To: BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY
Reel/Frame 020126/0032 →
Continuity (2)
Provisional Application 6084358900 · Sep 11, 2006
Related Publication 20080091027A1 · Apr 17, 2008